search
Back to results

Prophylaxis of COVID-19 Disease With Ivermectin in COVID-19 Contact Persons [German: Prophylaxe Der COVID-19-Erkrankung Mit Ivermectin Bei COVID-19 Kontaktpersonen]

Primary Purpose

Covid19

Status
Not yet recruiting
Phase
Phase 3
Locations
Study Type
Interventional
Intervention
Ivermectin
Placebo
Sponsored by
Infectopharm Arzneimittel GmbH
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Covid19 focused on measuring COVID-19 post-exposure prophylaxis

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • age of at least 18 years
  • adult subject living in the same household as a related COVID-19 patient (index person)

Exclusion Criteria:

  • index person has COVID-19 symptoms for more than 5 days at enrolment
  • known past COVID-19 or current infection confirmed by positive SARS-CoV-2 PCR test at enrolment
  • symptoms at enrolment indicating COVID-19: increased body temperature OR acute respiratory symptoms of any severity OR newly occuring loss of taste or smell OR ague OR sumulatneously occuring headache and body ache
  • known contraindications to the use of the study medication (in alignemnt with current summary of product characteristics of Driponin®)
  • known chronic obstructive pulmonary disease
  • known acute or chronic hepatitis B or C or other clinically recognizable or known liver dysfunction
  • known HIV infection or AIDS
  • known symptomatic allergic rhinitis
  • current (inlcuding up to 24 hours before enrolment) or planned (during next 14 days) therapy with non-steroidal anti-inflammatory drugs, other pain medication (e.g., ASS (including prophylactic use), metamizol)
  • recent (up to 28 days before enrolment) or planned (during next 14 days) therapy with systemic steroids
  • recent (up to 28 days before enrolment) or planned (during next 14 days) therapy with systemic immunosuppressive drugs
  • known or clinically suspected disturbance of the blood-brain-barrier (e.g., ABCB-1 (=MDR1) mutation) as well as history of neurotoxic effects by ivermectin or other substrates/inhibitors of the para-glycoprotein (P-gp)
  • known hypersensitivity/intolerance to the study drug or any of its exicpients, in particular ivermectin, microcrystalline cellulose, pre-agglutinated starch, butyl hydroxyanisole or magnesium stearate
  • pregnancy or lactation
  • women of child-bearing potential planning to become pregnant or not using effective mehods of contraception
  • any other severe disorder, which in the opinion of the investigator would preclude the subject from trial participation
  • previous or planned (during next 14 days) vaccination with any COVID-19 vaccine
  • recent (up to 28 days before enrolment) or planned (during next 14 days) therapy with Ivermectin
  • recent (up to 28 days before enrolment) or planned (during next 14 days) therapy with drugs with evident or potential benefit in treating COVID-19 in alignemnt with RKI
  • apparent unreliability or lack of compliance (e.g., not willing to orally administer the required number of tablets on 2 days or not willing to complete the subject diary during 14 days)
  • known alcohol or drug abuse
  • participation in another clinical trial during the last 30 days or planned participation in another clinical trial during the next 30 days
  • previous participation in this same clinical trial

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Experimental

    Placebo Comparator

    Arm Label

    Ivermectin

    Placebo

    Arm Description

    2 doses of ivermectin at day 0 and day 2

    2 doses of placebo at day 0 and day 2

    Outcomes

    Primary Outcome Measures

    COVID-19 disease
    Occurrence of a COVID-19 disease up to the final visit (day 14), defined as the presence of the clinical condition according to the RKI case definition (acute respiratory symptoms of any severity OR new loss of smell and taste occurred OR illness-related death) AND a positive SARS-CoV-2 PCR test on the day the symptoms were determined (+/- 4 days)

    Secondary Outcome Measures

    Adverse events and side effects
    Number and severity of adverse events and side effects.
    Type, number and severity of symptoms
    Type, number and severity of symptoms within the 14-day of study on subjects suffering from COVID-19 (incl. hospitalization, oxygen saturation and demand, intensive care treatment)
    Severity of the COVID-19 disease
    Severity of the COVID-19 disease according to the investigator's assessment

    Full Information

    First Posted
    September 28, 2021
    Last Updated
    November 1, 2021
    Sponsor
    Infectopharm Arzneimittel GmbH
    Collaborators
    GKM Gesellschaft für Therapieforschung mbH
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT05060666
    Brief Title
    Prophylaxis of COVID-19 Disease With Ivermectin in COVID-19 Contact Persons [German: Prophylaxe Der COVID-19-Erkrankung Mit Ivermectin Bei COVID-19 Kontaktpersonen]
    Official Title
    Placebo-controlled Randomized Double-blind Phase III Study on the Efficacy and Safety of Ivermectin Tablets (Driponin®) for the Prophylaxis of COVID-19 Disease in Adult Contact Persons Living in the Household of a Person Suffering From COVID-19 [German: Placebo-kontrollierte Randomisierte Doppel-blinde Phase III Studie Zur Wirksamkeit Und Sicherheit Von Ivermectin Tabletten (Driponin®) für Die Prophylaxe Der COVID-19 Erkrankung Bei im Haushalt Lebenden Erwachsenen Kontaktpersonen Einer an COVID-19 Erkrankten Person]
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    November 2021
    Overall Recruitment Status
    Not yet recruiting
    Study Start Date
    November 2021 (Anticipated)
    Primary Completion Date
    March 2022 (Anticipated)
    Study Completion Date
    March 2022 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    Infectopharm Arzneimittel GmbH
    Collaborators
    GKM Gesellschaft für Therapieforschung mbH

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    No
    Studies a U.S. FDA-regulated Device Product
    No
    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    The Prevent-COVID study is a prospective, multicenter, randomized, two-armed, placebo-controlled, double-blind, interventional study in which the efficacy and safety of ivermectin in COVID-19 post-exposure prophylaxis (PEP) is examined in adult, close family contacts living in the household of a subject suffering from COVID-19.
    Detailed Description
    Study population and study sites: The study is carried out in about 30 private practices or clinics in Germany that regularly carry out SARS-CoV-2 PCR tests and treat COVID-19 patients. Adult close contact persons of newly diagnosed COVID-19 patients living in the same household are considered for participation. Study duration and assessment: The study will last 14 days, in which the following study-specific measures will be undertaken: Documentation of demographics (age, gender, ethnicity, height and weight, degree of relationship to the COVID-19 patient) Documentation of current comorbidities Documentation of current medical accompanying measures Documentation of the general condition Vital signs COVID-19 symptoms SARS-CoV-2 PCR test: Only for medical confirmation of the presence of COVID-19 symptoms during an unplanned COVID-19 visit or final visit. Subject diary (daily measurement of body temperature, contact intensity with the index person) Pregnancy test in women of childbearing potential Objectives: Primary Objective: To demonstrate the efficacy of ivermectin in the COVID-19 post-exposure prophylaxis of adult contact persons living in the household of a person suffering from COVID-19 (index person) Secondary objectives: To demonstrate the safety of ivermectin in the COVID-19 post-exposure prophylaxis of adult contact persons living in the household of a person suffering from COVID-19 (index person) To determine the severity of the symptoms of subjects suffering from COVID-19 during the study period and the comparison between the ivermectin and the placebo group. IMP: Driponin® is an approved drug with the active ingredient Ivermectin, used to treat parasitic infections. One tablet Driponin® contains 3 mg Ivermectin. As part of the clinical trial, the medicinal product will be examined with regard to indication, dosage and application schedule deviating from the intended purpose and the package insert.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Covid19
    Keywords
    COVID-19 post-exposure prophylaxis

    7. Study Design

    Primary Purpose
    Prevention
    Study Phase
    Phase 3
    Interventional Study Model
    Parallel Assignment
    Masking
    ParticipantInvestigator
    Allocation
    Randomized
    Enrollment
    412 (Anticipated)

    8. Arms, Groups, and Interventions

    Arm Title
    Ivermectin
    Arm Type
    Experimental
    Arm Description
    2 doses of ivermectin at day 0 and day 2
    Arm Title
    Placebo
    Arm Type
    Placebo Comparator
    Arm Description
    2 doses of placebo at day 0 and day 2
    Intervention Type
    Drug
    Intervention Name(s)
    Ivermectin
    Other Intervention Name(s)
    Driponin, ATC-code P02CF01, Substance code SUB12089MIG
    Intervention Description
    2 doses of Ivermectin will be administered with 48 hours time interval. The dosage is based on body weight calculated as follows: 15 mg for 40-60 kg = 5 tablets à 3 mg 18 mg for 60-80 kg = 6 tablets à 3 mg 24 mg for > 80 kg = 8 tablets à 3 mg each This corresponds to an ivermectin dose of about 300 µg / kg.
    Intervention Type
    Drug
    Intervention Name(s)
    Placebo
    Intervention Description
    An analogous number of tablets is administered for placebo: 5 tablets for 40-60 kg 6 tablets for 60-80 kg 8 tablets for > 80 kg The size, appearance, smell and taste of the tablets of placebo are identical to Ivermectin.
    Primary Outcome Measure Information:
    Title
    COVID-19 disease
    Description
    Occurrence of a COVID-19 disease up to the final visit (day 14), defined as the presence of the clinical condition according to the RKI case definition (acute respiratory symptoms of any severity OR new loss of smell and taste occurred OR illness-related death) AND a positive SARS-CoV-2 PCR test on the day the symptoms were determined (+/- 4 days)
    Time Frame
    Day 14
    Secondary Outcome Measure Information:
    Title
    Adverse events and side effects
    Description
    Number and severity of adverse events and side effects.
    Time Frame
    14 days
    Title
    Type, number and severity of symptoms
    Description
    Type, number and severity of symptoms within the 14-day of study on subjects suffering from COVID-19 (incl. hospitalization, oxygen saturation and demand, intensive care treatment)
    Time Frame
    14 days
    Title
    Severity of the COVID-19 disease
    Description
    Severity of the COVID-19 disease according to the investigator's assessment
    Time Frame
    14 days

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Accepts Healthy Volunteers
    Accepts Healthy Volunteers
    Eligibility Criteria
    Inclusion Criteria: age of at least 18 years adult subject living in the same household as a related COVID-19 patient (index person) Exclusion Criteria: index person has COVID-19 symptoms for more than 5 days at enrolment known past COVID-19 or current infection confirmed by positive SARS-CoV-2 PCR test at enrolment symptoms at enrolment indicating COVID-19: increased body temperature OR acute respiratory symptoms of any severity OR newly occuring loss of taste or smell OR ague OR sumulatneously occuring headache and body ache known contraindications to the use of the study medication (in alignemnt with current summary of product characteristics of Driponin®) known chronic obstructive pulmonary disease known acute or chronic hepatitis B or C or other clinically recognizable or known liver dysfunction known HIV infection or AIDS known symptomatic allergic rhinitis current (inlcuding up to 24 hours before enrolment) or planned (during next 14 days) therapy with non-steroidal anti-inflammatory drugs, other pain medication (e.g., ASS (including prophylactic use), metamizol) recent (up to 28 days before enrolment) or planned (during next 14 days) therapy with systemic steroids recent (up to 28 days before enrolment) or planned (during next 14 days) therapy with systemic immunosuppressive drugs known or clinically suspected disturbance of the blood-brain-barrier (e.g., ABCB-1 (=MDR1) mutation) as well as history of neurotoxic effects by ivermectin or other substrates/inhibitors of the para-glycoprotein (P-gp) known hypersensitivity/intolerance to the study drug or any of its exicpients, in particular ivermectin, microcrystalline cellulose, pre-agglutinated starch, butyl hydroxyanisole or magnesium stearate pregnancy or lactation women of child-bearing potential planning to become pregnant or not using effective mehods of contraception any other severe disorder, which in the opinion of the investigator would preclude the subject from trial participation previous or planned (during next 14 days) vaccination with any COVID-19 vaccine recent (up to 28 days before enrolment) or planned (during next 14 days) therapy with Ivermectin recent (up to 28 days before enrolment) or planned (during next 14 days) therapy with drugs with evident or potential benefit in treating COVID-19 in alignemnt with RKI apparent unreliability or lack of compliance (e.g., not willing to orally administer the required number of tablets on 2 days or not willing to complete the subject diary during 14 days) known alcohol or drug abuse participation in another clinical trial during the last 30 days or planned participation in another clinical trial during the next 30 days previous participation in this same clinical trial

    12. IPD Sharing Statement

    Learn more about this trial

    Prophylaxis of COVID-19 Disease With Ivermectin in COVID-19 Contact Persons [German: Prophylaxe Der COVID-19-Erkrankung Mit Ivermectin Bei COVID-19 Kontaktpersonen]

    We'll reach out to this number within 24 hrs